title: Effect of cell permeable peptide of c-Jun NH2-terminal kinase inhibitor on the attenuation of renal ischemia-reperfusion injury in pigs.
abstract: The outcomes of organ transplantation have improved due to better immunosuppressive drugs, surgical techniques, and management of complications. However, ischemia-reperfusion injury remains a challenge affecting graft survival. In this study, we employed injection of a protein transduction domain (PTD) to inhibit the c-Jun NH2-terminal kinase (JNK) pathway thereby attenuating ischemia-reperfusion injury in a porcine model. The PTD-JNK inhibitor (JNKI) was administered into the renal artery, allowing it to be taken into various elements including vascular endothelial cells by endocytosis via the PTD. Serum creatinine and blood urea nitrogen concentrations were lower among PTD-JNKI than controls. In addition, renal tissue blood flow was maintained in the PTD-JNKI group, resulting in less tissue injury and fewer apoptotic cells. These results suggested that the PTD technique improved renal transplantation outcomes.
authors: Department of Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. datsushi@gmail.com
authors: A
authors: A
authors: Doi
authors: H
authors: H
authors: Kitada
authors: M
authors: M
authors: Ota
authors: S
authors: S
authors: Kawanami
authors: K
authors: K
authors: Kurihara
authors: Y
authors: Y
authors: Miura
authors: T
authors: T
authors: Nishiki
authors: Y
authors: Y
authors: Okabe
authors: S
authors: S
authors: Inoue
authors: M
authors: M
authors: Tanaka
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015415:Biomarkers / Q000097:blood; D001806:Blood Urea Nitrogen; D002463:Cell Membrane Permeability; D057846:Cell-Penetrating Peptides / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D050377:Cold Ischemia / Q000009:adverse effects; D003404:Creatinine / Q000097:blood; D019610:Cytoprotection; D004195:Disease Models, Animal; D004705:Endocytosis; D005260:Female; D007269:Injections, Intra-Arterial; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D012077:Renal Artery; D012079:Renal Circulation / Q000187:drug effects; D015427:Reperfusion Injury / Q000201:enzymology / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D013552:Swine; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D015415:Biomarkers; D057846:Cell-Penetrating Peptides; D047428:Protein Kinase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D003404:Creatinine; D048031:JNK Mitogen-Activated Protein Kinases